UBS Group Has Lowered Expectations for Corteva (NYSE:CTVA) Stock Price

Corteva (NYSE:CTVA – Get Free Report) had its price objective reduced by stock analysts at UBS Group from $15.00 to $10.00 in a research report issued on Friday, Benzinga reports. The firm currently has a “neutral” rating on the stock. UBS Group‘s price objective would indicate a potential upside of 6.21% from the company’s previous close.

CTVA has been the topic of several other research reports. KeyCorp upgraded shares of Corteva from a “sector weight” rating to an “overweight” rating and set a $17.00 price objective on the stock in a report on Wednesday, October 7th. Bank of America boosted their target price on shares of Corteva from $90.00 to $96.00 and gave the stock a “buy” rating in a research report on Monday, July 20th. Morgan Stanley restated an “overweight” rating and issued a $18.00 target price on shares of Corteva in a report on Friday, October 2nd. Zacks Research cut shares of Corteva from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 6th. Finally, JPMorgan Chase & Co. upgraded Corteva from a “neutral” rating to an “overweight” rating and set a $19.00 price target for the company in a research note on Tuesday, October 6th. Fifteen equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $52.60.

Read Our Latest Analysis on Corteva

Corteva Stock Up 2.4%

NYSE CTVA traded up $0.23 on Friday, hitting $9.41. 28,888,260 shares of the company were exchanged, compared to its average volume of 21,957,566. The company has a current ratio of 1.56, a quick ratio of 1.10 and a debt-to-equity ratio of 0.14. The company has a market cap of $6.28 billion, a PE ratio of 4.96, a PEG ratio of 1.72 and a beta of 0.58. The stock has a fifty day moving average of $37.22 and a 200-day moving average of $69.57. Corteva has a 12 month low of $9.01 and a 12 month high of $90.97.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in shares of Corteva during the 2nd quarter worth approximately $4,560,180,000. Wellington Management Group LLP lifted its stake in Corteva by 941.7% in the second quarter. Wellington Management Group LLP now owns 7,612,704 shares of the company’s stock valued at $644,720,000 after purchasing an additional 6,881,875 shares during the last quarter. Royal Bank of Canada lifted its stake in Corteva by 202.1% in the first quarter. Royal Bank of Canada now owns 7,458,624 shares of the company’s stock valued at $624,362,000 after purchasing an additional 4,989,371 shares during the last quarter. Jupiter Topco LLC bought a new position in Corteva during the second quarter valued at $544,246,000. Finally, Bank of America Corp DE bought a new position in Corteva during the second quarter valued at $484,927,000. 81.54% of the stock is owned by institutional investors.

Key Headlines Impacting Corteva

These are some of the CTVA headlines that stood out recently:

  • Positive Sentiment: Corteva pointed to new products and cost-cutting efforts as supports for a potential recovery, though these measures have not offset near-term weakness. Corteva Q3 Earnings Call Highlights Brazil Woes and Outlook Cut
  • Neutral Sentiment: Several analysts lowered price targets following the outlook reset. Citigroup and UBS kept neutral ratings, while JPMorgan maintained overweight and RBC kept outperform ratings, signaling some analysts still see potential upside from recent levels. Read More. · Read More. · Read More. · Read More.
  • Negative Sentiment: The earnings miss and lowered full-year outlook are the key near-term headwinds, with Brazil weakness and competitive pricing hurting results. Reuters report on Brazil weakness and forecast cut

Corteva Company Profile

(Get Free Report)

Corteva, Inc. is an agricultural science company that develops and supplies products and services for farmers. Its business focuses on seeds and crop protection, including technologies intended to help improve crop performance and manage weeds, insects, and plant diseases. Its seed portfolio includes corn, soybean, and other crop varieties, sold under brands such as Pioneer and Brevant. Corteva’s crop protection offerings include herbicides, insecticides, fungicides, and biological products, alongside digital tools and services that support farm decision-making.

Further Reading

Analyst Recommendations for Corteva (NYSE:CTVA)

Receive News & Ratings for Corteva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corteva and related companies with MarketBeat.com's FREE daily email newsletter.